select a format

Single User License
USD 250 INR 16030
Site License
USD 500 INR 32060
Corporate User License
USD 750 INR 48090

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Ono Pharmaceutical Co Ltd (4528)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Ono Pharmaceutical Co Ltd (4528)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH31988D
  • |
  • Pages: 211
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Ono Pharmaceutical Co Ltd(Ono Pharmaceutical) is a research-based pharmaceutical company, which carries out the discovery, production and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes Rivastach, Glactiv, Forxiga, Emend, Staybla, Recalbon, Opalmon, Onon, Kinedak, Foipan, Opdivo and Orencia. Ono Pharmaceutical products find application in the treatment of diseases such as type II diabetes, overactive bladder, osteoporosis, Alzheimer's disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. It also has many other products in pipeline development. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusion. It works in partnerships with various biopharmaceutical companies, academic and research institutions across the globe. It has operational presence in Japan, Taiwan, South Korea, the UK and the US. Ono Pharmaceutical is headquartered in Chuo-ku, Osaka, Japan.

Ono Pharmaceutical Co Ltd (4528)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 10

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 11

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 12

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 13

Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 14

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19

Partnerships 19

Receptos Expands Collaboration With Ono Pharma For GPCR Technology Platform 19

Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 20

X-Chem Enters into Agreement with Ono Pharma 20

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 21

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 23

Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 25

Dako Enters into Development Agreement with ONO PHARMA for Opdivo 26

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 26

Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 27

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 28

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 30

Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 31

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 32

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 32

Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 33

Receptos Enters Into R&D Agreement With Ono Pharma 34

Progenra Enters Into Research Agreement With Ono Pharma 35

Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharma 36

Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharma For ORENCIA 38

Ono Pharma Extends Research Agreement With Evotec 39

Ono Pharma Enters Into Agreement With Dainippon Sumitomo For Limaprost Alfadex 40

Xention Extends Collaboration With Ono Pharma 41

Ono Pharma Enters Into Co-Development Agreement With BioFocus 42

Licensing Agreements 43

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 43

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 44

ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 45

ONO Pharma Enters into Licensing Agreement with Celyad 45

Santen Pharma Enters into Licensing Agreement with Ono Pharma 46

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 47

Ono Pharma Enters into Licensing Agreement with Merus 48

Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 49

Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 50

Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 51

Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 52

Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169 53

Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine 54

Ono Pharma Enters Into Licensing Agreement With OncoTherapy 55

Ono Pharmaceutical Co Ltd-Key Competitors 57

Key Employees 58

Locations And Subsidiaries 60

Head Office 60

Other Locations & Subsidiaries 60

Recent Developments 62

Strategy And Business Planning 62

Mar 01, 2016: Completion of the new Research Building (The Third Building) in the Minase Research Institute 62

Financial Announcements 63

Dec 21, 2016: ONO PHARMACEUTICAL: Revisions of Consolidated Financial Forecasts 63

Government and Public Interest 64

Jul 27, 2016: Infusion of Nearly $35.4 Million in Grant Funding to Support Roswell Park Research 64

Product News 66

12/08/2016: Immunotherapy combination shows promise in advanced bladder cancer 66

12/07/2016: EU green light for nivolumab in blood cancer as new data show promising benefits 67

12/06/2016: Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032 68

11/24/2016: NICE Issues Evidence Based Recommendations on Nivolumab for Previously Treated Advanced RCC 70

11/15/2016: Biodesixs Diagnostic Cortex Platform Used In Three Studies Presented at SITC 72

11/08/2016: Biodesix Presenting Results From Three Studies at SITC Annual Meeting; Oral Poster Presentation, Two Additional Poster Presentations 74

11/03/2016: Bristol-Myers Squibb to Present New Data On Opdivo at the 58th Annual Meeting & Exposition of the American Society of Hematology 76

10/31/2016: New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma 78

10/20/2016: Defining the True Value of Innovation in Cancer Treatment 80

10/14/2016: Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin 81

10/10/2016: ESMO 2016: PD-L1 Expression as a Biomarker for Checkpoint Inhibitors Response in Patients with Advanced Melanoma 82

10/07/2016: Neoadjuvant Immunotherapy Prior to Surgery is Safe and Feasible in Early Lung Cancer 83

09/07/2016: ONO Receives Approval for OPDIVO (nivolumab) Intravenous Infusion for Treatment of Unresectable or Metastatic Renal Cell Carcinoma in Japan as Part of Partial Change in Approved Items of Manufacturing and Marketing Authorization 84

08/08/2016: SMC 'U-turn' offers lifeline to Scottish skin cancer patients 85

08/05/2016: Bristol-Myers Squibb Statement on Top-Line Results from CheckMate -026 86

08/04/2016: Gene expression profile may ID renal cell carcinoma pts unlikely to benefit from nivolumab 87

07/11/2016: Scots first to receive breakthrough immunotherapy for lung cancer 88

07/06/2016: Cancer survival lottery intensifies as NICE says 'no' to Opdivo (nivolumab) for kidney cancer patients 89

06/29/2016: Bristol-Myers Squibb's Response to ICER's Draft Scoping Document "Treatment Options for Advanced Non-Small-Cell Lung Cancer" 90

06/08/2016: Canada health technology assessment agency gives positive recommendation for OPDIVO to treat non-small cell lung cancer 91

06/05/2016: Nivolumab immunotherapy helps patients with advanced bladder cancer 92

05/18/2016: Breadth and Depth of Bristol-Myers Squibb's Immuno-Oncology Clinical Development Program to be Showcased at 2016 American Society of Clinical Oncology Annual Meeting 93

05/09/2016: ONO PHARMA TAIWAN Receives Approval of OPDIVO (Nivolumab) for New Drug Application for Unresectable or Metastatic Melanoma and Metastatic Squamous Non-Small Cell Lung Cancer in Taiwan 99

04/11/2016: ONO Announces Sales Results of OPDIVO (Nivolumab), Antineoplastic Agent for Fiscal Year 2015 and its Sales Forecasts for Fiscal Year 2016 100

04/04/2016: ONO PHARMA KOREA Receives Approval for OPDIVO (Nivolumab) for Expanded Application of Unresectable or Metastatic Melanoma and Additional Indication of Locally Advanced or Metastatic Non-small Cell Lung Cancer Refractory to Existing Chemotherapy in South Korea 101

04/01/2016: Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) for Treatment of Advanced Melanoma 102

03/30/2016: European Medicines Agency Validates Bristol-Myers Squibb's Application for Opdivo (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients 103

03/24/2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy 104

03/24/2017: ONO Receives Approval for OPDIVO (Nivolumab) Intravenous Infusion for Treatment of Recurrent or Metastatic Head and Neck Cancer as a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan 105

03/22/2017: Ontario Latest Province to Cover Cost of Immuno-Oncology Treatment OPDIVO (nivolumab) 106

03/15/2017: Manitoba to Cover Immuno-Oncology Treatment OPDIVO (nivolumab) for Three Tumour Types 107

03/02/2017: British Columbia to Cover Immuno-Oncology Treatment OPDIVO (nivolumab) for Three Tumour Types 108

02/02/2017: Bristol-Myers Squibb Company Received Approval for Nivolumab by U.S. Food and Drug Administration for Treatment of Urothelial Carcinoma 109

Jan 26, 2016: ONO PHARMACEUTICAL Selects Medidata to Power Clinical Trials Exploring Additional Cancer Indications for Immunotherapy Drug OPDIVO 110

01/22/2016: NICE 'yes' for Opdivoq offers patients with advanced skin cancer new treatment option 111

Product Approvals 112

Apr 04, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer 112

Dec 27, 2016: ONO Submits Supplemental Application of OPDIVO (Nivolumab) for Unresectable Advanced or Recurrent Gastric Cancer for a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan 113

Nov 22, 2016: European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin 114

Nov 10, 2016: Bristol-Myers Squibb's Opdivo (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer 116

Nov 04, 2016: First early access scheme for breakthrough immunotherapy in blood cancer 118

Oct 21, 2016: NICE U-turn brings breakthrough immunotherapy to kidney cancer patients 119

Oct 21, 2016: U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer 120

Oct 14, 2016: NICE review to deny around two-thirds of lung cancer patients potentially life-extending medicine 121

Sep 29, 2016: FDA Modifies the Dosage Regimen for Currently Approved Indications for Nivolumab 122

Sep 20, 2016: European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer 123

Sep 13, 2016: Modification of the Dosage Regimen for Nivolumab 124

Aug 03, 2016: NICE Issues Technology Appraisal Guidance for Nivolumab in Combination With Ipilimumab for Advanced Melanoma 125

Jul 27, 2016: ONO Submits Supplemental Application of OPDIVO (Nivolumab) for Recurrent or Metastatic Head and Neck Cancer for a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan 126

Jul 18, 2016: Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 127

May 17, 2016: Opdivo (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA 129

May 12, 2016: NICE no for lung cancer patients 131

Apr 25, 2016: Bristol-Myers Squibb's Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 133

Apr 25, 2016: Health Canada Approves OPDIVO (nivolumab) for the treatment of Advanced or Metastatic Renal Cell Carcinoma 134

Apr 14, 2016: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Supplemental Biologics License Application for Opdivo (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients 136

Apr 13, 2016: Opdivo approved in Europe in two more cancers: most common forms of lung and kidney cancer 137

Apr 06, 2016: European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma 138

Apr 06, 2016: European Commission Approves Expanded Use of Opdivo (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer 140

Apr 06, 2016: European Commission Approves Expanded Use of Opdivo to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer 142

Mar 18, 2016: ONO Submits Supplemental Application of OPDIVO (Nivolumab) for Additional Indication of Relapsed or Refractory Hodgkin's Lymphoma 143

Mar 01, 2016: Health Canada approves OPDIVO (nivolumab) for the treatment of advanced or metastatic non-small cell lung cancer 144

Feb 29, 2016: ONO Receives Approval for OPDIVO (Nivolumab) for a Partial Change in Approved Items for Treatment of Unresectable Melanoma in Japan 146

Feb 26, 2016: Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo (nivolumab) for Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer and Renal Cell Carcinoma 148

Feb 26, 2016: New treatment for advanced form of kidney cancer 149

Feb 05, 2016: First immunotherapy EAMS for most common type of lung cancer brings UK patients access to life-extending medicine, nivolumab 150

Jan 23, 2016: Bristol-Myers Squibb's Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 151

Clinical Trials 153

Apr 03, 2017: Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme 153

Apr 03, 2017: Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer, in Phase 1 Study CA209-003 154

Apr 03, 2017: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma 155

Apr 02, 2017: Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials 157

Jan 19, 2017: Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study 158

Dec 08, 2016: New data show immunotherapy combination may double survival in lung cancer patients 160

Dec 05, 2016: Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012 Study 161

Dec 05, 2016: Immunotherapy agent yields full and partial remissions in aggressive non-Hodgkin lymphomas 163

Dec 02, 2016: OPDIVO (nivolumab) Intravenous Injection Receives Approval for Supplemental Indication of Relapsed or Refractory Classical Hodgkin Lymphoma in Japan 164

Nov 16, 2016: Bristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress and Leadership in Broad Lung Development Program 165

Nov 10, 2016: Opdivo (nivolumab) Demonstrates Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study 166

Oct 25, 2016: New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients 167

Oct 10, 2016: UPCI-tested immunotherapy prolongs life, reduces side effects and improves quality of life 169

Oct 09, 2016: Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer 170

Oct 09, 2016: Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer 172

Oct 09, 2016: Opdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study 173

Oct 08, 2016: Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer 175

Oct 03, 2016: New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach 177

Aug 09, 2016: Esophageal & Lung Institute of Allgheny Health Network Launches Study of Immunotherapy Drug For Advanced Esophageal Cancer 182

Aug 09, 2016: Influence of Cliical Results from CheckMate-026, a Phase III Study of Opdivo (nivolumab) in Treatment-Nave Patients with Advanced Non-Small Cell Lung Cancer 183

Aug 05, 2016: Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Nave Patients with Advanced Non-Small Cell Lung Cancer 184

Jun 27, 2016: Bristol-Myers Squibb Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer 185

Jun 10, 2016: New Data on Bristol-Myers Squibbs Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial 186

Jun 09, 2016: Bristol-Myers Squibb to Present New Data on Opdivo (nivolumab) at the 21st Congress of the European Hematology Association 188

Jun 06, 2016: Immunotherapy improves survival, quality of life in rapidly progressing head and neck cancer 189

Jun 05, 2016: First Presentation of Phase 2 CheckMate -142 Study Evaluating Opdivo (nivolumab) Alone or in Combination with Yervoy (ipilimumab) Demonstrates Encouraging Clinical Activity in MSI-High Metastatic Colorectal Cancer 190

Jun 05, 2016: Long-Term Survival and Improvement in Quality of Life Observed with Opdivo (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting 192

Jun 05, 2016: Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer 194

Jun 04, 2016: Nivolumab Extends Survival for Patients with Advanced Kidney Cancer Treated Beyond Disease Progression 195

Jun 02, 2016: Two-drug immunotherapy deemed safe for lung cancer patients, Moffitt study shows 196

May 25, 2016: An Immunotherapy Drug, OPDIVO, Is Found To Improve Long-Term Overall Survival for Patients with Advanced Lung Cancer 197

May 24, 2016: Two-Year Overall Survival Data from Two Pivotal Opdivo Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer 198

May 20, 2016: Continued Treatment with Nivolumab May Improve Survival in Patients with Advanced Kidney Cancer 199

May 18, 2016: Two-Year Overall Survival Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer 200

Apr 26, 2016: NIHR Cancer study has Groundbreaking results 202

Apr 19, 2016: First Presentation of Overall Survival Data for Opdivo (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigator's Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 203

Apr 17, 2016: First Presentation of Two-Year Overall Survival Data for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma 205

Apr 15, 2016: First-ever nivolumab study to treat aggressive anal cancer appears promising 207

Mar 16, 2016: Bristol-Myers Squibb to Present New Overall Survival Data for Opdivo (nivolumab) as Monotherapy and in Combination with Yervoy (ipilimumab) at the AACR 2016 Annual Meeting 208

Jan 28, 2016: CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early 210

Appendix 211

Methodology 211

About GlobalData 211

Contact Us 211

Disclaimer 211

List of Figures

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 10

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 11

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 12

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 13

Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 14

List of Tables

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 10

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 11

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 12

Ono Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 13

Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 14

Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15

Receptos Expands Collaboration With Ono Pharma For GPCR Technology Platform 19

Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 20

X-Chem Enters into Agreement with Ono Pharma 20

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 21

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 23

Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 25

Dako Enters into Development Agreement with ONO PHARMA for Opdivo 26

Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 26

Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 27

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 28

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 30

Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 31

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 32

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 32

Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 33

Receptos Enters Into R&D Agreement With Ono Pharma 34

Progenra Enters Into Research Agreement With Ono Pharma 35

Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharma 36

Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharma For ORENCIA 38

Ono Pharma Extends Research Agreement With Evotec 39

Ono Pharma Enters Into Agreement With Dainippon Sumitomo For Limaprost Alfadex 40

Xention Extends Collaboration With Ono Pharma 41

Ono Pharma Enters Into Co-Development Agreement With BioFocus 42

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 43

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 44

ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 45

ONO Pharma Enters into Licensing Agreement with Celyad 45

Santen Pharma Enters into Licensing Agreement with Ono Pharma 46

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 47

Ono Pharma Enters into Licensing Agreement with Merus 48

Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 49

Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 50

Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 51

Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 52

Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169 53

Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine 54

Ono Pharma Enters Into Licensing Agreement With OncoTherapy 55

Ono Pharmaceutical Co Ltd, Key Competitors 57

Ono Pharmaceutical Co Ltd, Key Employees 58

Ono Pharmaceutical Co Ltd, Other Locations 60

Ono Pharmaceutical Co Ltd, Subsidiaries 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ono Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com